Evidence map›Paper›PMID 20134397›Full record

ArticleTransplantation2010

NOD-scid IL2rgamma(null) mouse model of human skin transplantation and allograft rejection.

Waldemar J Racki, Laurence Covassin, Michael Brehm, Stephen Pino, Ronald Ignotz, Raymond Dunn, Joseph Laning, Susannah K Graves, Aldo A Rossini, Leonard D Shultz and 1 more

Open access · greenAbstract read
In one paragraph

Article in Transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Best practices in mouse models of skin transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Blank Spots in the Map of Human Skin: The Challenge for Xenotransplantation.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Xenograft Skin Model to Manipulate Human Immune Responses In Vivo.Journal of visualized experiments : JoVE · 2022
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Evolution of ischemia and neovascularization in a murine model of full thickness human wound healing.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Waldemar J RackiDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
Laurence Covassin
Michael Brehm
Stephen Pino
Ronald Ignotz
Raymond Dunn
Joseph Laning
Susannah K Graves
Aldo A Rossini
Leonard D Shultz
Dale L Greiner
University of Massachusetts Chan Medical School · USCollege of the Atlantic · US

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI Jeffrey Hsu-Min Chuang · 1985 to 2026
$61.9M
Virology and Technology CoreP01AI046629 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GREINER, DALE LESLIE · 1999 to 2014
$19.1M
PILOT AND FEASIBILITY PROGRAMP30DK032520 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CZECH, MICHAEL P · 1986 to 2010
$14.6M
ROLE OF CBL AND PHOSPHATIDYLINOSITOL 3-KINASE IN CD40 SIGNALINGP01DK053006 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ROCK, KENNETH L · 1997 to 2007
$8.9M
Adaptive immunity in virus-induced diabetes in BBDR ratsU01AI073871 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GREINER, DALE LESLIE · 2006 to 2011
$2.9M
Molecular Genetics and Mechanisms of ThrombocytopeniaR01HL077642 · NHLBI · JACKSON LABORATORY · PI SHULTZ, LEONARD D. · 2004 to 2007
$1.7M
NCI NIH HHS CA34196NCI NIH HHS P30 CA034196NHLBI NIH HHS HL077642NHLBI NIH HHS R01 HL077642NIAID NIH HHS AI46629NIAID NIH HHS P01 AI046629NIAID NIH HHS U01 AI073871NIDDK NIH HHS DK32520NIDDK NIH HHS P01 DK053006NIDDK NIH HHS P30 DK032520
6 · The paper itself

Abstract

backgroundTransplantation of human skin on immunodeficient mice that support engraftment with functional human immune systems would be an invaluable tool for investigating mechanisms involved in wound healing and transplantation. Nonobese diabetic (NOD)-scid interleukin-2 gamma chain receptor (NSG) readily engraft with human immune systems, but human skin graft integrity is poor. In contrast, human skin graft integrity is excellent on CB17-scid bg (SCID.bg) mice, but they engraft poorly with human immune systems.

methodsHuman skin grafts transplanted onto immunodeficient NSG, SCID.bg, and other immunodeficient strains were evaluated for graft integrity, preservation of graft endothelium, and their ability to be rejected after engraftment of allogeneic peripheral blood mononuclear cells.

resultsHuman skin transplanted onto NSG mice develops an inflammatory infiltrate, consisting predominately of host Gr1(+) cells, that is detrimental to the survival of human endothelium in the graft. Treatment of graft recipients with anti-Gr1 antibody reduces this cellular infiltrate, preserves graft endothelium, and promotes wound healing, tissue development, and graft remodeling. Excellent graft integrity of the transplanted skin includes multilayered stratified human epidermis, well-developed human vasculature, human fibroblasts, and passenger leukocytes. Injection of unfractionated, CD4 or CD8 allogeneic human peripheral blood mononuclear cell induces a rapid destruction of the transplanted skin graft.

conclusionsNSG mice treated with anti-Gr1 antibody provide a model optimized for both human skin graft integrity and engraftment of a functional human immune system. This model provides the opportunity to investigate mechanisms orchestrating inflammation, wound healing, revascularization, tissue remodeling, and allograft rejection and can provide guidance for improving outcomes after clinical transplantation.

Indexed as

AnimalsAntigens, CDErythrocytesFlow CytometryGraft RejectionHumansLeukocyte Common AntigensLeukocyte TransfusionMiceMice, Inbred NODMice, SCIDReceptors, Interleukin-2Skin TransplantationSpleenTransplantation, HeterologousTransplantation, HomologousAntigens, CDLeukocyte Common AntigensReceptors, Interleukin-2

Identifiers

PMID20134397
PMCPMC2901915
OpenAlexW2066802833

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.